Canadian Kidney Transplant Professionals' Perspectives on Precision Medicine and Molecular Matching in Kidney Allocation
- PMID: 38111837
- PMCID: PMC10727564
- DOI: 10.1097/TXD.0000000000001565
Canadian Kidney Transplant Professionals' Perspectives on Precision Medicine and Molecular Matching in Kidney Allocation
Abstract
Background: Antibody-mediated rejection is an important cause of kidney transplant loss. A new strategy requiring application of precision medicine tools in transplantation considers molecular compatibility between donors and recipients and holds the promise of improved immunologic risk, preventing rejection and premature graft loss. The objective of this study was to gather Canadian transplant professionals' perspectives on molecular compatibility in kidney transplantation.
Methods: Seventeen Canadian transplant professionals (14 nephrologists, 2 nurses, and 1 surgeon) participated in semistructured interviews in 2021. The interviews were digitally recorded, transcribed, and analyzed using the qualitative description approach.
Results: Participants identified fair access to transplantation as the most important principle in kidney allocation. Molecular compatibility was viewed as a promising innovation. However, participants were concerned about increased waiting times, negative impact on some patients, and potential problems related to the adequacy of information explaining this new technology. To mitigate the challenges associated with molecular matching, participants suggested integrating a maximum waiting time for molecular-matched kidneys and expanding the program nationally/internationally.
Conclusions: Molecular matching in kidney transplantation is viewed as a promising technology for decreasing the incidence of antibody-mediated rejection and improving graft survival. Further studies are needed to determine how to ethically integrate this technology into the kidney allocation algorithm.
Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors declare no conflicts of interests.
Similar articles
-
Canadian Kidney Transplant Recipients', Transplant Candidates', and Caregivers' Perspectives on Precision Medicine and Molecular Matching in Kidney Allocation: A Qualitative Analysis.Can J Kidney Health Dis. 2025 May 23;12:20543581251342440. doi: 10.1177/20543581251342440. eCollection 2025. Can J Kidney Health Dis. 2025. PMID: 40417412 Free PMC article.
-
Adding epitope compatibility to deceased donor kidney allocation criteria: recommendations from a pan-Canadian online public deliberation.BMC Nephrol. 2023 Jun 9;24(1):165. doi: 10.1186/s12882-023-03224-z. BMC Nephrol. 2023. PMID: 37296384 Free PMC article.
-
Public values and guiding principles for implementing epitope compatibility in kidney transplantation allocation criteria: results from a Canadian online public deliberation.BMC Public Health. 2023 May 10;23(1):844. doi: 10.1186/s12889-023-15790-w. BMC Public Health. 2023. PMID: 37165330 Free PMC article.
-
HLA compatibility and organ transplant survival. Collaborative Transplant Study.Rev Immunogenet. 1999;1(3):334-42. Rev Immunogenet. 1999. PMID: 11256424 Review.
-
Interventions for preventing thrombosis in solid organ transplant recipients.Cochrane Database Syst Rev. 2021 Mar 15;3(3):CD011557. doi: 10.1002/14651858.CD011557.pub2. Cochrane Database Syst Rev. 2021. PMID: 33720396 Free PMC article.
Cited by
-
Anti-Human Leukocyte Antigen Antibody Detection from Terasaki's Humoral Theory to Delisting Strategies in 2024.Int J Mol Sci. 2025 Jan 13;26(2):630. doi: 10.3390/ijms26020630. Int J Mol Sci. 2025. PMID: 39859344 Free PMC article. Review.
-
Canadian Kidney Transplant Recipients', Transplant Candidates', and Caregivers' Perspectives on Precision Medicine and Molecular Matching in Kidney Allocation: A Qualitative Analysis.Can J Kidney Health Dis. 2025 May 23;12:20543581251342440. doi: 10.1177/20543581251342440. eCollection 2025. Can J Kidney Health Dis. 2025. PMID: 40417412 Free PMC article.
-
Molecular matching tools for allocation and immunosuppression optimization. Ready for primetime?Curr Opin Organ Transplant. 2025 Feb 1;30(1):30-36. doi: 10.1097/MOT.0000000000001185. Epub 2024 Nov 12. Curr Opin Organ Transplant. 2025. PMID: 39711242 Free PMC article. Review.
References
-
- Canadian Institute for Health Information. Treatment of END-STAGE ORGAN FAILURE in Canada, Canadian Organ Replacement Register, 2012 to 2021: end-stage kidney disease and kidney transplants—data tables. 2023.
-
- Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–399. - PubMed
-
- Amore A. Antibody-mediated rejection. Curr Opin Organ Transplant. 2015;20:536–542. - PubMed
-
- Muduma G, Odeyemi I, Smith-Palmer J, et al. Review of the clinical and economic burden of antibody-mediated rejection in renal transplant recipients. Adv Ther. 2016;33:345–356. - PubMed
-
- Haririan A. Current status of the evaluation and management of antibody-mediated rejection in kidney transplantation. Curr Opin Nephrol Hypertens. 2015;24:576–581. - PubMed
LinkOut - more resources
Full Text Sources